JC virus detection and JC virus-specific immunity in natalizumab-treated multiple sclerosis patients by R. Mancuso et al.
Mancuso et al. Journal of Translational Medicine 2012, 10:248
http://www.translational-medicine.com/content/10/1/248RESEARCH Open AccessJC virus detection and JC virus-specific immunity
in natalizumab-treated Multiple Sclerosis patients
Roberta Mancuso1*, Marina Saresella1, Ambra Hernis1, Ivana Marventano1, Cristian Ricci1, Simone Agostini1,2,
Marco Rovaris1, Domenico Caputo1 and Mario Clerici1,2Abstract
Background: The use of natalizumab in multiple sclerosis (MS) may favour JC virus reactivation; this phenomenon
is usually asymptomatic but can, albeit rarely, evolve into frank progressive multifocal leucoencephalopathy (PML).
Methods: JCV-specific CD8+ T lymphocytes were evaluated by flow cytometry over a 24-month period in 24
natalizumab-treated MS patients in whom JCV DNA was or was not detected in blood using quantitative real-time
polymerase chain reaction; all these cases were asymptomatic.
Results: Perforin- and grazymes-containing VP-1-specific CD8+ T lymphocytes were reduced whereas
CD107a-expressing cells were increased in JCV positive patients, suggesting an active degranulation of these cells;
naïve CD8+ T lymphocytes were also decreased whereas memory cells were increased in patients in whom JCV
reactivation was observed.
Conclusion: The presence of a CD8+ T lymphocyte-mediated effector immune response offers a greater insight
into reactivation of JCV and its clinical sequelae, and may help the monitoring of patients on natalizumab therapy.
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Natalizumab is a monoclonal antibody that binds the
alpha-chain of integrins and is used in the therapy of
Multiple Sclerosis (MS). Results of longitudinal studies
confirmed the efficacy of such treatment, as the annual
relapse rate evaluated after 1 year was reduced by 68%
whereas the disability progression over 2 years was
diminished by 42% in natalizumab–treated compared to
placebo patients [1]. These results notwithstanding, a
worrisome possible adverse effect of natalizumab is the
development of progressive multifocal leucoencephalo-
pathy (PML); recent results reported more than 200
cases of PML in natalizumab patients, with an overall
incidence (1.01/1000 patients) with the greatest increase
in risk occurring after 2 years of therapy [2]. PML is a
severe demyelinating disease due to the lytic replication
of human polyomavirus JC virus (JCV) in oligodendro-
cytes. PML occurs when immunosurveillance within the
central nervous system (CNS) is impaired; no effective* Correspondence: rmancuso@dongnocchi.it
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reproduction in any medium, provided the ortherapy is known for this condition. Risk factors for
natalizumab-associated PML are still unknown. One hy-
pothesis suggests that natalizumab could block lympho-
cyte trafficking through the blood–brain barrier, this
would results in a decrease of immunosurveillance
allowing JC virus reactivation from latency. Notably, this
effect would be specific for JC virus as other opportunistic
infections are only occasionally reported in natalizumab-
treated MS patients [3]. Natalizumab seems also to
influence bone marrow physiology. Thus, possibly as a
consequence of a blocking effect of this drug on the α4β1/
VCAM-1 interaction -a process pivotal in favoring the
generation of T cells and B cells from bone marrow (BM)
progenitors [4]- a rapid egress of CD34+ cells from the
BM was observed [5]. This would create an environment
favoring the reactivation of JC virus within the bone mar-
row [6,7].
To date, there are no methods that can reliably predict
which patients have a higher risk of developing PML as
no clear-cut associations can be established between
JCV DNA in the blood or urine or JCV viremia and
viruria and PML [8-11]. In the attempt to bypass thisal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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suggested to be a sensitive tool to identify patients at a
reduced risk of PML development [12]; complementary
tests of JCV DNA in urine were also indicated as being
useful for the stratification of risk of PML in patients [13],
as the detection of urinary viral DNA identifies JCV
infected subject when antibody are still undetectable.
Whereas JCV viruria is frequently detected in healthy
individuals, the appearance of JCV DNA in blood of
such individuals is very rare. JCV-specific antibodies
are present in about 58% of healthy individuals [14],
but JCV reactivation and the development of PML are
very seldomly observed in healthy subjects, possibly
because the virus is kept at bay by cell mediated im-
munity. Supporting this idea are the observations that:
1) detection of JCV-specific cytotoxic T lymphocytes
(CTL) in the peripheral blood of individuals with PML
was shown to be a positive prognostic marker [15]; and
2) JCV-specific CTL were suggested to protect against
the development of PML in JCV-infected immunocom-
petent individuals [16].
The mechanism underlying JC viral replication are
nevertheless still unknown, and the influence of natali-
zumab on JCV control is unclear. We monitored the
asymptomatic reactivation of JCV in peripheral blood of
JCV infected MS patients treated with natalizumab over
a 24-month period. Changes in cell mediated immunity
parameters were compared between patients with or
without JCV reactivation.
Methods
Study population
Twenty-four outpatients with a diagnosis of MS [17]
(4 males, 20 females) were enrolled in the study at the
Multiple Sclerosis Center of Don Gnocchi Foundation
(Scientific Institute S. Maria Nascente, Milan, Italy)
between November 2007 and June 2011. Patient’s mean
age (± standard deviation) was 37 ± 10 years; mean
disease duration was 12 ± 8 years with a mean Expanded
Disability Status Scale (EDSS) at enrollment of 4.0 ± 1.4.
One of the patients had never been treated with
disease-modifying drugs. Among the other 23 patients,
15 (65%) previously underwent immunomodulating
therapies (interferon, glatiramer acetate); the other 8
individuals (35%) were treated with immunosuppres-
sive drugs (mitoxantrone, azathyoprine). No significa-
tive differences were observed concerning the type of
previous therapy, disease duration, or wash-out period
prior to natalizumab in patients in whom JCV reactiva-
tion was or was not observed during therapy. All
patients fulfilled the Italian Agency of Drug (AIFA)
criteria for natalizumab treatment i.e. they either were
affected by a particularly severe disease course in the
year prior to therapy (marked clinical worsening; highrelapse rate; rapid disability accumulation), or they
showed a lack of response to previous immunosup-
pressive or immunomodulatory therapies.The washout
period before initiating natalizumab was 3 months for
patients previously using immune-modifying drugs,
and 6 months for patients undergoing immunosup-
pressive therapy (mandatory according to AIFA
guidelines).
Urine, blood and serum samples collected at baseline
and after 1 (Mo. 1), 6 (Mo. 6), and 12 (Mo. 12) and 24
(Mo. 24) months of therapy, at the time of infusion,
were utilized for JCV quantitative detection. An ad-
ditional series of samples was collected within one
month in the case of the detection of JC virus DNA
positivity during treatment with monthly natalizumab
infusions for 24 consecutive months. Finally, although not
mandatory according to the AIFA guidelines, cerebro-
spinal fluid (CSF) analysis for JCV DNA were performed
before the initiation of therapy as well as after 24
months of treatment (number of infusion: median 24,
range 24–28). Written, informed consent was obtained
from each patient; the study was approved by the local
ethics committee.
JCV-specific cellular immunity was prospectively eva-
luated using frozen peripheral blood mononuclear cells
(PBMCs) specimens in 5 patients in whom JCV DNA
was detected in blood (nr. 1–5 in Figure 1) and in 5 sub-
jects in whom JCV DNA was never detected during
follow-up (acting as controls) (nr. 8–12 in Figure 1).
Immunological analyses were performed at baseline and
after 1 (Mo. 1), 6 (Mo. 6), 12 (Mo. 12) and 24 (Mo 24)
months of therapy.
Blood sample collection
Whole blood was collected by venepuncture in Vacu-
tainer tubes containing ethylenediamine tetra-acetic
acid (EDTA) (Becton Dickinson & Co., Rutherford,
NJ). PBMCs were separated on lymphocyte separation
medium (Organon Teknika Corp., Durham, NC) and
washed twice in phosphate-buffered saline (PBS); the
number of viable leukocytes was determined by trypan
blue exclusion.
Detection of JCV antibodies
After the activation of a centralized service supported by
a grant from Biogen Idec (STRATIFY project), enzyme
linked assay (ELISA) was performed to detect antibodies
specific for JCV virus-like particles [12] in serum of 23/
24 enrolled subjects treated for a 24-month period.
Detection of viral genome by qPCR
DNA was extracted from 150 μl of cell-free CSF, serum,
or urine using the spin-columns technique, or from
5x106 PBMCs (Nucleospin virus kit and Nucleospin
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to the manufacturer instructions. Detection and quantifica-
tion of JCV DNA was performed by qPCR targeting the
large T-antigen gene of JCV genome, following a previously
described protocol [18]. Limit of detection (LOD) was 2
copies/μl of extracted DNA (corresponding to 10 copies/re-
action or 500 copies/ml of CSF or serum or urine, or 40
copies/μg of DNA from PBMCs). All samples were assayed
in triplicate, leading to 3 fold increasing of analytical sensi-
tivities (166 copies/ml or 2.3 Log10; 13 copies/μg DNA or
1.1 Log10). Samples resulting positive in only one replicate
were re-extracted and retested in triplicate.
All laboratory procedures were carried out under
stringent conditions to avoid contamination. In details,
samples were processed individually and DNA extrac-
tions were performed one at time, in a clean, dust-free
area with sterile and disposable materials, with a change
of gloves for each sample.
Selection and synthesis of VP-1peptides binding to MHC
molecules
The VP-1 JCV protein was chosen since this protein has
been shown to be preferentially recognized by CD8+ T
lymphocytes [19]. Binding properties of VP-1 peptides to
Class I molecules were predicted using the RANKPEP
program (Molecular Immunology Foundation at the site
http://www.mifoundation.org/Tools/rankpep.html).
Fourteen 9 mer with high score and two 9 mer VP-1
peptides with the lowest score were selected, as anti-
genic and negative controls respectively, to evaluate
HLA-I-restricted JCV specific responses. Peptides were
synthesized using Fmoc chemistry; their purity, as
assayed by HPLC, was >70% and their composition
was verified by mass spectrometry [20]. Lyophilized
peptides were dissolved at 25mg/ml in DMSO or ste-
rile water to prepare peptide pools (10 μg/ml final
concentration).
All the peptides have been previously used to asses
JCV- specific immune responses by proliferation assay
and intracellular cytokine production. Preliminary
experiments (data not shown) were performed with
PBMC of 5 PML patients and 5 healthy controls (HC);
results confirmed previously published data [21,22].
CFSE proliferation assay and intracellular cytokine
detection in unstimulated PBMC or in PBMC that were
stimulated with the VP-1 peptide pools or the peptide
control pool confirmed that proliferation of IFN-γ or
TNF- α-producing CD8+ T cells could be detected upon
stimulation with the antigenic VP-1 peptides alone.
VP-1-specific CD8+ T cell subsets
1x106 PBMCs were placed in polystyrene tissue culture
plates containing 1 ml RPMI +10% AB human serum, 10
μl of CD107a [23], and either non-immunogenic(unstimulated) or VP-1 peptides. Plates were incubated
at 37°C in a humidified 5% CO2 atmosphere for 5 hours.
Brefeldin A (Sigma) (final concentration 10 μg/ml), was
added after 1 hour of incubation. Cells were then har-
vested, washed with phosphate-buffered saline (PBS),
stained with an anti-CD8 mAb, and incubated 30 min
at RT in the dark. Cells were subsequently washed
with PBS and 100 μl of Saponin 0.5% was added to
permeabilize the cell surface. Ten μl of IFN-γ, TNF-α,
perforin- and granzyme-specific mAb were then added
to the cells that were finally washed with PBS and resus-
pended in 500 μl of PFA 1%.
VP-1 specific-CD8+ T cell Subsets
1x106 PBMCs were placed in polystyrene tissue culture
plates containing 1ml RPMI +10% AB human serum,
and either non-immunogenic (unstimulated) or VP-1
peptides for 5 hours at 37°C in a humidified 5% CO2
atmosphere. Cells were then harvested, washed with
PBS, stained with an anti-CD8 anti-CD45RA and anti-
CCR7 mAb, and incubated 30 min at RT in the dark.
Finally stained cells were fixed in 500 μl of PFA 1%. The
following CD8+ Tcell subsets were analyzed by flow-
cytometry: naïve (CD8+45RA+CCR7+), central memory
(CM) (CD8+45RA-CCR7+), effector memory (EM)
(CD8+45RA-CCR7-) and terminally differentiated (TD)
(CD8+45RA+CCR7-).
Monoclonal antibodies (mAbs)
The following mAbs were used: anti-Phycoerythrin-Cya-
nin-7 (PC7)-labeled anti-CD4 (clone SFCI12T4D11),
Phycoerythrin-Cyanin-5 (PC5)-labeled anti-CD8 (clone
B9.11), Phycoerythrin (PE)-labeled anti-CD3 (UCHT1)
(IgG1), FITC-labeled anti-TNFα- (MP9-20A4), PE-labeled
anti-IFNγ- (B27)(both m IgG1) (Invitrogen-Caltag Lab
Carlsbad, CA, USA), FITC-conjugated anti-perforin (δG9)
(m IgG2b), and PE conjugated anti-granzyme- (GB11)
(m IgG1) (Becton-Dickinson Biosciences, San Jose CA,
USA) anti-human CD107a PE-labeled (clone H4a3, iso-
type mouse IgG 1k BD Biosciences, San Jose, CA) as well
as isotype-matched mouse mAbs were also utilized.
Statistical analysis
Statistical analysis of prevalence data at each time point
in urine, serum and blood samples were carried out with
two-sided Fisher’s exact test. Quantitative continuous
variables (JCV viral load) were not normally distributed
and comparisons were performed using non parametric
test. A repeated measures analysis of variance was used
to investigate for variable change (perforin, granzyme,
CD107a) after virus activation. In this model measures
following virus activation were marked as dummy and
within-subject analysis was performed. The P value on
the graph was performed by Fisher’s method for
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P values from Mann–Whitney U-test comparing sub-
ject with virus activation to subject without virus acti-
vation at any observation across time. Independent
measures hypothesis was tested by means of Hoeffding
test. All statistical evaluation was performed by SAS
software vers.9.2.
Results
Clinical outcome
A clearly positive outcome of the study was that no
PML cases developed during the follow-up period.
Clinical relapses during the 24-month period of therapy
were observed in 7/24 patients; anti-natalizumab anti-
bodies were detected in one of these cases. All these
patients were successfully treated with IV methylpredni-
solone (IVMP) for 3 days and natalizumab treatment
was continued. Data of 5 of the patients in whom a
relapse during follow up was observed are presented in
Figure 1 (nr. MS1, MS8, MS10, MS12,MS14); DNA
could never be isolated from the other 2 individuals and,
as a consequence, data of these 2 patients are not shown
in this figure.
Twenty-four patients, reached a follow-up of 24
months. The clinical efficacy of Natalizumab was con-
firmed by the observation that the EDSS remain stable,
or was reduced in 23/24 patients (96%). Mean EDSS
score showed a reduction from baseline (4.0 ± 1.4) to
post–treatment (3.8 ± 1.6) even if it the changes were
not statistically significant (p=0.61).
JCV in urine, serum, PBMCs and CSF
JCV was detected at baseline and/or during follow-up in
urine, serum and/or PBMCs in 14/24 (58%) patients.
Figure 1 shows virological data obtained from these 14
patients; JCV DNA was never observed in the remaining
10 individuals.
JCV was observed in urine in 11/14 cases, in serum in
4/14 individuals, and in PBMCs in 4/14 cases. JCV was
detected in multiple sites (e.g. urine and serum) in 4/14
patients whereas it was present in a single specimen in
the other 10 cases (see Figure 1). No differences were
observed between the JCV-positive and the JCV-negative
patients either in age or gender (data not shown). All
the CSF samples tested were JCV negative both at base-
line and after 24 months of treatment (Figure 1).
Anti–JCV antibodies
12/24 (50%) individuals resulted seropositive for JCV.
Only in 3 of these cases seropositivity did not coincide
with JCV detectability by qPCR. In 3 other cases the
opposite situation was observed: thus, these 3 patients
were JCV seronegative but JCV DNA could bedetected by qPCR (two in urine, 1in PBMC; MS7,
MS8, MS10 in Figure 1).Longitudinal assessment of JCV in MS patients
JCV in urine
Consistent with other studies [24,25] the overall fre-
quency of JCV viruria was 28% at baseline, and respect-
ively 12%, 24%, 20% and 16% after 1, 6, 12, and 24,
months of natalizumab treatment. JCV viruria was
detected in at least one sample during follow-up in 11/
24 (42%) cases (Table 1); no significant differences were
observed in JCV viral load in urine (Log10 copies/ml)
when baseline results (median: 5.54, IQR: 4.96-5.97)
were compared to data obtained at the different time of
follow-up (Mo1: 5.77, 5.66-5.90; Mo6: 5.59, 4.94-5.62;
Mo12: 5.26, 4.15-5.94; Mo24: 5.73, 4.78-6.67).
Longitudinal analysis of virus detection in JCV positive
patients is shown in Figure 1; JCV viruria was observed
frequently at a single time point, but only in one case
(patient 6) a persistent JCV viruria during the follow-up
was detected; notably this was the only individuals in
whom JCV was detected in all three investigated sites
(urine, serum, PBMCs), without any evidence of PML.JCV in blood
JCV was detected in peripheral blood in 7 patients (two
cases in PBMC at baseline; five cases in serum/PBMC
during treatment): in all these patients JCV was negative
in subsequent samples (within one month after the posi-
tivity). Median JCV DNA viral load in PBMC was 2.45
Log10 copies/μg DNA; JCV DNA median viral load in
serum was 3.53 Log10 copies/ml (Figure 1).Cytokine-producing CD8+ T lymphocytes
JCV-specific cell mediated immune parameters were
evaluated in 5 patients in whom JCV DNA was detected
in peripheral blood (JCV POS: patients nr. 1–5 in
Figure 1) during treatment, and in 5 subjects in whom
JCV was never detected during follow-up in peripheral
blood (JCV NEG: patients nr. 8–12 in Figure 1).
VP-1-stimulated tumour necrosis factor-alpha (TNF-
α)- and interferon-gamma (IFN-γ) - producing CD8+ T
lymphocytes were measured to determine possible mo-
difications in the frequency of cytokine-producing circu-
lating VP-1-stimulated T cells. A repeated measures
analysis of variance was used to investigate for variable
change in patients with virus reactivation in blood. In
this model, measures following virus activation were
marked as dummy and within-subject analysis was
performed. Intra-subjects analysis of results did not
show the presence of significant variations in any of the
cytokines analyzed in two groups analyzed (Figure 2).
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Figure 1 Longitudinal testing of samples from Multiple Sclerosis patients positive for JCV DNA in urine, and/or serum, and/or PBMCs.
Black boxes correspond to positive samples, white boxes to negative samples. JCV viral load (VL) is indicated for each positive sample and
median value are shown at the bottom. Patients with PBMCs analyzed for JCV-specific immunity are underlined. For each patient anti-JCV
antibody status and any clinical relapse (*) during follow up are also indicated.
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T lymphocytes
Perforin and granzymes mediate the destruction of
virus-infected cells upon being released by antigen-
specific CD8+ T lymphocytes; VP-1-stimulated gran-
zymes and perforin containing CD8+ T lymphocytes
were analyzed in both groups of patients. Results
showed that VP1-stimulated perforin- and granzyme-
containing CD8+ T cells were differently expressed in
JCV POS compared to JCV NEG patients (Figure 3);
notably the levels of both proteins was reduced in JCVTable 1 JCV detection in urine, serum and PBMCs of
natalizumab-treated MS patients
Patients (nr) Median VLa Median VL (IQR)b
PBMCs 4/24* 3 x 102 2.45 (2.28-3.11)
serum 4/24#† 3.75 x 103 3.53 (3.11-3.82)
urine 11/24*† 4.1 x 105 5.60 (5.08-5.84)
a Viral loads (VL) are expressed as viral copies/ml in urine and in serum, as
copies/μg of DNA in PBMCs. bVL median values and interquartile range (IQR)
are expressed as Log10 copies.
* † Fisher exact test : PBMCs or serum vs. urine p= 0.062.POS individuals. The differences reached statistical
significance in the case of perforin.VP-1-stimulated CD107a-expressing CD8+ T lymphocytes
CD107a is expressed on the surface of CD8+ cytotoxic T
lymphocytes upon degranulation. CD107a-expressing
VP-1-specific CD8+ T cells were analyzed in all patients;
a repeated measures analysis of variance was used to
investigate for variable change in patients with virus
reactivation in blood. Results indicate that these cells
were significantly augmented in JCV POS patients, sug-
gesting that CD8+ T cells do indeed degranulate in
response to viral DNA (Figure 3).VP-1-specific CD8 T cell subsets
Subsetes of VP-1-specific naïve and memory CD8+ T lym-
phocytes were examined next. The following lymphocytes
subsets were analyzed: naïve (CD8+/CDRA+/CCR7+), CM
(Central Memory: CD8+/CDRA-/CCR7+), EM (Effector
Memory: CD8+/CDRA-/CCR7-) and TD (Terminally Dif-
ferentiated: CD8+/CDRA+/CCR7-) cells. Results showed
Figure 2 VP-1 stimulated IFN-γ and TNF-α cytokine-producing CD8+ T lymphocytes in Multiple Sclerosis patients undergoing
natalizumab. Results obtained over a 24 months period are shown; grey dots indicate subject in whom virus activation in blood was not
detected (JCV NEG); black dots indicate individuals in whom JCV DNA was detected in blood (JCV POS). Error bars depict first and third quartiles
and median values are indicated. Statistical significance is presented.
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diminished (PRE: median 54%, IQR48-54; POS 50%, IQR
48–56; POST: 43%, IQR 18–50) whereas effector memory
(CD8+/RA-/CCR7-) (PRE: 21%, IQR 16–33; POS: 26%,
IQR 24–31; POST: 26%, IQR 26–53) as well as terminally
differentiated (CD8+/RA+/CCR7-) (PRE: 12%, IQR
7–13; POS: 17%, IQR 10–14.5; POST 19%, IQR 12–17)
lymphocytes were increased in JCV POS individuals
(Figure 4). Because differentiation of naïve T lymphocytes
into memory populations is contingent upon antigen
recognitions, these results indeed suggest that JCV repli-
cation took place in JCV POS patients during follow-up.
Discussion
JC virus, the cause of PML, a demyelinating disease of
the central nervous system observed in immune-compromised individuals, is one of the most prevalent
viruses in humans. Thus, urinary excretion is common
in healthy Europeans [26,27], and JCV DNA viruria is
detectable in about one half of healthy peoples living
in Italy [28]. Notably, long-term or continuous JCV
urinary excretion has been observed in 20 to 50% of
healthy individuals [27], with a wide variation of the
quantities of JCV excreted in urine within different
subjects [29].
It recently became clear that the use of natalizumab,
a monoclonal antibody used in the therapy of MS, can
result in the reactivation of JCV in CNS [30]. The con-
nection between natalizumab and JCV reactivation is
not known, even if it appears clear that alterations in
immunosurveillance within the CNS are involved in
this phenomenon. The effect of natalizumab on JCV in
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Figure 3 VP-1 stimulated perforin-, granzyme-, or CD107a-expressing- CD8+ T lymphocytes in Multiple Sclerosis patients undergoing
natalizumab. Left Column: Results obtained during a 24 months period; grey dots indicate subject in whom virus activation in blood was not
detected (JCV NEG); black dots indicate individuals in whom JCV DNA was detected in blood (JCV POS). Error bars depict first and third quartiles.
Statistical significance is shown. Right Column: Representative results obtained in JCV NEG (A, C, E) or in JCV POS (B, D, F) patients. In the upper
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some authors [31,32] reported the frequent detection
of asymptomatic JCV reactivation in the urinary tract
after therapy; these observations were nevertheless not
replicated in other analyses [24,25].
It is debated whether the detection of JCV in blood
and/or plasma results in a higher likelihood to develop
PML. Thus, JCV DNA can sometimes be detected in
blood in healthy individuals [33,34], but viral load in
blood is usually very low even in patients with a diag-
nosis of PML [35]. The connection between JCV and
PML is nevertheless reinforced by the observations
that: 1) the estimated hypothetical PML incidence in
JCV Ab-negative patients is extremely low (0.09 cases
per 1000 patients) [2]; and 2) no PML cases have ever
been reported in JCV Ab-negative individuals [36].
Humoral immunity alone cannot control JCV replication
[37-39] as JCV shedding in urine of immunocompetentindividuals is very common, suggesting that also cellular
immunity seems to be not very efficient in JCV replication
control [14].
To verify whether correlations could be observed
between the appearance of JCV DNA in blood and the
elicitation of virus-specific cell mediated immunity we
analyzed this arm of the immune response in patients in
whom blood viral DNA was, or was not, detected.
Results herein show that a reduced quantity of VP-1-
stimulated CTL containing the proteins that, upon
degranulation, are responsible for the destruction of
virus infected target cells via lytic (perforin) and apop
totic (granzymes) mechanisms is observed in those
patients n whom JCV DNA was detected in blood.
CD107a is expressed by CTL only when these cells
release perforin and granzymes. Notably, VP-1-specific
CD107a-expressingCD8+ T lymphocytes were increased
in patients in whom JCV DNA was detected during
Figure 4 Memory/Naïve T lymphocyte subsets. Relative proportions of VP-1 stimulated CD8+naïve (CCR7+CD45RA+), central memory (CM:
CCR7+CD45RA-), effector memory (EM: CCR7-CD45RA-), and terminally differentiated (TD: CCR7-CD45RA+) T lymphocytes in Multiple Sclerosis
patients undergoing natalizumab. Samples were tested at baseline (PRE), at the time of JCV DNA isolation in blood (POS), and after 24 months of
therapy (POST).
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JCV-specific perforin- and granzymes-positive lympho-
cytes is a consequence of degranulation i.e. of an active
virus-specific and CTL-mediated immune response.
That virus replication indeed occurred in a subset of
natalizumab-treated patients is further confirmed by the
observation that a differentiation from naïve toward
effector phenotypes of VP-1-specific CD8+ T lympho-
cytes was observed in such patients.
Conclusions
Taken together these results indicate that the appear-
ance of JCV DNA in blood of natalizumab treated
MS patients is an event associated with the differen-
tiation of virus-specific cells and the elicitation of a
CD8+ T lymphocyte-mediated immune effector re-
sponse. It is tempting to speculate that this response
is responsible for the containment of JCV reactivation
and for preventing the clinical consequences of such
reactivation.JCV-specific cellular immune responses were recently
shown to diminish over time in natalizumab-treated MS
patients in whom viremia developed [31].
Our results, even if obtained in a small group of
patients and needing to be replicated and expanded,
offer a mechanistic explanation justifying on an im-
munological basis why the appearance of JCV DNA in
blood does not result in symptomatic JCV reactivation;
moreover it is necessary to consider, as previously sug-
gested [14], that JCV replication (shedding in urine)
could be not necessarily a sign of T cell disfunction, but
instead reflect differences in presentation and/or proces-
sing of viral antigens, anatomic location and/or accessi-
bility to T cells.
This study was designed to compare MS patients in
whom JCV did or did not reactivate during therapy;
given high prevalence of JCV infection in the population
at-large it will be interesting to verify JCV-specific CMI
in JCV- infected healthy individuals.
A final consideration is that, based on the preliminary
results herein, investigating the impact of new monoclonal
Mancuso et al. Journal of Translational Medicine 2012, 10:248 Page 9 of 10
http://www.translational-medicine.com/content/10/1/248therapies (e.g. efalizumab, rituximab, infliximab) on virus
specific cell mediated immune response could be useful
to better clarify the mechanisms associated with JCV
reactivation.
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